Atopic Dermatitis

While topical therapies may suffice for mild-to-moderate atopic dermatitis, systemic agents may become necessary for more severe disease. Peter Lio, M.D., discusses his approach to treatment utilizing available therapies.

Crisaborole ointment, 2%, (Eucrisa, Pfizer) appears to be safe and effective in children aged three months to less than 24 months who have mild-to-moderate atopic dermatitis, according to results of a phase 4 trial released yesterday.

Researchers tested whether diluted bleach solution at the concentrations recommended for bleach baths is an effective antibacterial agent.

In this Medical News Minute, Dr. Bobby Lazzara discusses the specifics regarding injection site reactions.

Are you training your patients on how to use their self-injectable medications safely and effectively? If not, you may want to start, according to researchers of a recent study, which examined patient behavior surrounding self-injection devices.

As a class, JAK inhibitors look like the best oral targeted therapeutic option when topical cortical steroids and/or topical calcineurin inhibitors plus emollients fail.

In our first Irregular Borders column, Peter A. Lio, M.D., explores the evidence for leaky gut and its relevance in dermatology while highlighting parallels with impaired skin barrier function in conditions such as atopic dermatitis.

Because a patient’s atopic dermatitis may also have a profound effect on parental caregivers, clinicians should seek to make an assessment of parental emotional and psychosocial well-being, and offer patient educational materials to help bring awareness to the issue.

Have you ever found yourself on the other side of the stethoscope? That’s what happened when Dr. Wheeland awoke one day with an asymptomatic, solitary, round, scaly patch on his ankle. Read how this experience inspired him to take a second look at how he treats patients with eczema.

“Pretty much, I couldn’t go about my normal life,” says Benjamin Sun about a life-altering eczema flare up at age 9, which left him out of school and bedridden for weeks. Until now, children like Sun didn’t have an effective, safe option for long-term disease control. Read how dupilumab changed his quality of life, and what it can do for your pediatric patients with uncontrolled moderate to severe atopic dermatitis.

Despite evidence that topical cannabinoids may relieve symptoms, more research is needed.

The differential diagnosis of atopic dermatitis can be challenging. Our expert, Dr. Robert Lazarra, highlights the basic criteria you need to know in this video.

Mothers of children with atopic dermatitis may be more likely to experience difficulty falling asleep, insufficient sleep and daytime exhaustion, according to a recent study. 

Unlike prior generations of dermatologic drugs, Janus kinase (JAK) inhibitors show potential for treating numerous dermatologic indications. Brett King, M.D., Ph.D. explored what this class of drug has to offer in his presentation during AAD earlier this month.

In the future, atopic dermatitis (AD) may need to be targeted with different drugs and tailored for different AD populations, particularly if initial treatment targeting all phenotypes fails, says Emma Guttman-Yassky, M.D., Ph.D.

New atopic dermatitis treatment developments earn “hot topic” status at AAD.

The development of new biologics targeting a variety of dermatoses is on the upswing with some treatments coming to the clinic as early as this year, according to April Armstrong, M.D. who discussed the topic at the American Academy of Dermatology Spring Meeting in Washington, D.C.

Dr. Lawrence Eichenfield discusses a better understanding of disease pathogenesis, available therapies and proactive treatment approach improves the outlook for managing atopic dermatitis.

Dr. Jonathan Silverberg offers tips at AAD 2019 for diagnosing and managing atopic dermatitis in adults.

Healthcare disparities exist in all fields of medicine, including dermatology. We seek to address these disparities in this article by outlining the differences in epidemiology, presentation, access and outcomes of five conditions in patients with skin of color.

The FDA has reversed a long-standing guidance stating that sponsors of clinical trials for atopic dermatitis (AD) in pediatrics need not start the trial in adults first. Here's what you need to know.

Asana BioSciences announced that the U.S. Food and Drug Administration granted fast-track designation for the investigational ASN002, an oral treatment for moderate-to-severe atopic dermatitis. Learn more in this article.

The National Psoriasis Foundation and the National Eczema Association have awarded Procter & Gamble’s Tide Free and Gentle Liquid Laundry Detergent and Tide PODS Free and Gentle Laundry Detergent a “Seal of Recognition” and “Seal of Acceptance” for people with eczema or sensitive skin.

Before 2018 comes to a close, we wanted to say thank you to our readers from everyone here at Dermatology Times. As a thank you, we have compiled a list of the topics and issues you found most compelling throughout the year. Enjoy this slideshow - and see you in 2019!

Patients with moderate-to-severe atopic dermatitis are at high risk of having inadequate disease control, according to a cross-sectional study in JAMA Dermatology.

Severe case of dupilumab-associated conjunctivitis successfully managed without discontinuing therapy.

In this article, Dr. Peter A. Lio discusses how recent advances in atopic dermatitis have led to a new standard of care, which aims to keep patients clear safely and maximize improvements in quality of life.

Cosmetic products with prebiotics, probiotics and postbiotics may be beneficial in treating eczema, a physician reported at the Fall Clinical Dermatology Conference held earlier this month in Las Vegas.